{"task_id": "0fa429c77ff13606", "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 872/905)", "text": "1\u201391. https://www.ncbi.nlm.nih.gov/pubmed/12843738\n\n--- Page 878 ---\n864\nReferences\n7 Patel AM, Goldfarb S. Got calcium? Welcome to the calcium-alkali syndrome. J Am Soc Nephrol 2010; \n9:1440\u20133. http://jasn.asnjournals.org/content/21/9/1440.long\n8 Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol 2002; 29(6 \nSuppl 21):12\u201318. https://www.ncbi.nlm.nih.gov/pubmed/12584690\n9 LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet com-\nmon practice. Ann Intern Med 2008; 149:259\u201363. https://www.ncbi.nlm.nih.gov/pubmed/18711156 \n10 Robey RB, Lash JP, Arruda JA. Does furosemide have a role in the management of hypercalcemia? Ann \nIntern Med 2009; 150:146\u20137. https://www.ncbi.nlm.nih.gov/pubmed/19153420\n11 Fitzpatrick LA. The hypocalcemic states. In: Favus M (ed) Disorders of bone and mineral metabolism. \nPhiladelphia, PA: Lippincott Williams & Wilkins, 2002:568\u201388\n12 Kramer HJ, Choi HK, Atkinson K, et al. The association between gout and nephrolithiasis in men: The \nHealth Professionals\u2019 Follow-Up Study. Kidney Int 2003; 64:1022\u20136. https://www.ncbi.nlm.nih.gov/pub-\nmed/12911552\n13 Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women \nfrom the UK. Osteoporos Int 2008; 19:385\u201397. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267485/\n14 NICE. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary \nprevention of osteoporotic fragility fractures in postmenopausal women [TA160]. 2008, updated 2011. \nhttps://www.nice.org.uk/Guidance/ta160\n15 Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal \nwomen. Cochrane Database Syst Rev 2011; 7:CD000333. http://onlinelibrary.wiley.com/doi/10.1002/14651858.\nCD000333.pub2/abstract\n16 Gillespie WJ. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev \n2010; 10:CD001255. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001255.pub4/abstract\n17 Eberling P. Osteoporosis in men. N Engl J Med 2008; 358:1474\u201382. http://www.nejm.org/doi/full/10.1056/\nNEJMcp0707217\n18 Vollbrecht J, Rao DS. Tumor-induced osteomalacia. N Engl J Med 2008; 358:1282. http://www.nejm.org/\ndoi/full/10.1056/NEJMicm066066#t=article\n19 Wermers RA, Tiegs RD, Atkinson EJ, et al. Morbidity and mortality associated with Paget\u2019s disease of \nbone: a population study. J Bone Miner Res 2008; 23:819\u201325. https://www.ncbi.nlm.nih.gov/pmc/articles/\nPMC2515478/\n20 NICE. Chronic kidney disease: Early identi\ufb01 cation and management of chronic kidney disease in \nadults in primary and secondary care [CG73]. 2008. https://www.nice.org.uk/guidance/cg73\n21 Anon. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the \nScandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383\u20139. https://www.ncbi.nlm.nih.gov/\npubmed/7968073\n22 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with \nhypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301\u20138. \nhttp://www.nejm.org/doi/full/10.1056/NEJM199511163332001#t=article\n23 Sacks FM, Pfeff er MA, Moye LA, et al. The eff ect of pravastatin on coronary events after myocardial \ninfarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investiga-\ntors. N Engl J Med 1996; 335:1001\u20139. http://www.nejm.org/doi/full/10.1056/NEJM199610033351401#t=article\n24 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lower-\ning with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; \n360:7\u201322. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)09327-3/abstract\n25 Libby P. In\ufb02 ammation in atherosclerosis. Nature 2002; 420:868\u201374. http://www.nature.com/nature/jour-\nnal/v420/n6917/full/nature01323.html\n26 Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Effi  cacy of statins in familial hypercholester-\nolaemia: a long term cohort study. BMJ 2008; 337:a2423 https://www.ncbi.nlm.nih.gov/pmc/articles/\nPMC2583391/\n27 NICE. Cardiovascular disease: Risk assessment and reduction, including lipid modi\ufb01 cation [CG181]. \n2014, updated 2016. https://www.nice.org.uk/guidance/CG181\n28 McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the Na-\ntional Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 8A:89C\u201394C. https://\nwww.ncbi.nlm.nih.gov/pubmed/16581336\n29 Robinson JG, Farnier M, Krempf M, et al. Effi  cacy and safety of alirocumab in reducing lipids and cardio-\nvascular events. N Engl J Med 2015; 372(16):1489\u201399. http://www.nejm.org/doi/full/10.1056/NEJMoa1501031\nChapter 15: Eponymous syndromes\n1 Todd J. The syndrome of Alice in Wonderland. Can Med Assoc J 1955; 73(9):701\u20134. https://www.ncbi.nlm.\nnih.gov/pmc/articles/PMC1826192/\n2 Cau C. The Alice in Wonderland syndrome. Minerva Med 1999; 90(10):397\u2013401. https://www.ncbi.nlm.nih.\ngov/pubmed/10767914\n3 Fritschy D, Fasel J, Imbert JC, et al. The popliteal cyst. Knee Surg Sports Traumatol Arthrosc 2006; \n14(7):623\u20138. https://www.ncbi.nlm.nih.gov/pubmed/16362357\n4 Scheinfeld NS. Erythema induratum (nodular vasculitis). Medscape. 2016. http://emedicine.medscape.\ncom/article/1083213-overview\n5 Hakim A, Gavin Clunie G, Haq I. Beh\u00e7et\u2019s disease. In: Oxford Handbook of Clinical Rheumatology (3rd \nedn). Oxford: Oxford University Press, 2011:490\u20131.\n6 Mariotti AJ, Agrawal R, Hotaling AJ. The role of tonsillectomy in pediatric IgA nephropathy. Arch Otolar-\nyngol Head Neck Surg 2009; 135(1):85\u20137. https://www.ncbi.nlm.nih.gov/pubmed/19153312\n7 Fourcade G, Bengler C, Campello CH, et al. [Bickerstaff \u2019s syndrome presenting with coma, tetraplegia and \nblindness]. Rev Neurol (Paris) 2007; 163(2):231\u20134. https://www.ncbi.nlm.nih.gov/pubmed/17351542\n8 Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diag-\nnosis and management of Barrett\u2019s oesophagus. Gut 2014; 63(1):7\u201342. http://gut.bmj.com/content/63/1/7.long\n9 Tham T. Guidelines on the diagnosis and management of Barrett\u2019s oesophagus - an update 2015. \n[Online \nonly] \nhttp://www.bsg.org.uk/clinical-guidelines/oesophageal/guidelines-on-the-diagnosis-and-\nmanagement-of-barrett-s-oesophagus.html", "text_length": 6384, "metadata": {"source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 872/905)", "type": "chunk", "chunk_index": 871, "total_chunks": 905, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T17:59:53.689816", "document_uuid": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f", "filename": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf", "category": "medical_pdf", "section": "body", "year": 2017, "outdated": false, "document_id": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f"}, "created_at": "2025-12-11T17:59:53.690560", "status": "complete", "chunks_added": 4}